Spero Therapeutics, Inc. Overview
Pro stress-test →Spero Therapeutics is dedicated to delivering differentiated medicines to help patients suffering from rare diseases and multidrug-resistant (MDR) bacterial infections. The company has achieved a significant milestone with its lead asset tebipenem HBr, an oral carbapenem candidate that represents a potential first-in-class treatment for complicated urinary tract infections.
Strategic Profile
Pro stress-test →In May 2025, Spero and GSK announced that the PIVOT-PO Phase 3 trial evaluating tebipenem HBr has met its primary endpoint and will stop early for efficacy. The company's partnership with GSK provides development and commercialization support, positioning Spero as a specialized biopharmaceutical developer focused on high unmet medical needs in niche therapeutic areas where approved options are limited.
Competitive Landscape
Pro stress-test →Spero operates in the niche antibiotic development space, competing with other specialized biotech firms developing novel treatments for MDR infections. The company's focus on oral carbapenems and rare diseases positions it distinctly from larger pharmaceutical firms, with primary competitive pressure from other clinical-stage developers and potential large pharma entrants. The partnership with GSK provides differentiated access to development and commercial resources.
Industry Context
Spero Therapeutics, Inc. operates in Biopharmaceutical Development - Specialty Focus (MDR Infections & Rare Diseases).
Key facts
Founded: 2013 · Headquarters: Cambridge, MA, US